Corcept Therapeutics Incorporated
CORT
$71.65
$1.191.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -13.57% | -0.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.57% | -0.36% | |||
| Cost of Revenue | -18.71% | 3.10% | |||
| Gross Profit | -13.48% | -0.41% | |||
| SG&A Expenses | 8.74% | 13.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.81% | 15.21% | |||
| Operating Income | -86.48% | -45.79% | |||
| Income Before Tax | -69.91% | -39.63% | |||
| Income Tax Expenses | -1,000.25% | -78.81% | |||
| Earnings from Continuing Operations | -33.17% | -34.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.17% | -34.88% | |||
| EBIT | -86.48% | -45.79% | |||
| EBITDA | -85.51% | -45.56% | |||
| EPS Basic | -33.53% | -35.09% | |||
| Normalized Basic EPS | -70.06% | -39.80% | |||
| EPS Diluted | -33.41% | -37.73% | |||
| Normalized Diluted EPS | -70.23% | -42.06% | |||
| Average Basic Shares Outstanding | 0.45% | 0.26% | |||
| Average Diluted Shares Outstanding | 1.15% | 4.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||